Top

Published in:

01-05-2015 | Research Article

Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy

Authors: Jie Zhou, Shikun Qian, Hongsheng Li, Weixing He, Xiaojun Tan, Qiong Zhang, Guodong Han, Guiquan Chen, Rongcheng Luo

Published in: Tumor Biology | Issue 5/2015

Abstract

Tau is a member of microtubule-associated proteins (MAPs) and expressed in normal breast epithelium and breast cancer cells. Tau expression levels in early breast cancer were correlated with the responsiveness of taxane-containing chemotherapy. However, it is unknown whether Tau contributes to breast cancer progression. Herein, Tau expression in recurrent and metastatic breast cancer (RMBC) and its predictive significance in taxane-containing palliative chemotherapy were investigated. Immunohistochemical (IHC) staining was conducted to detect Tau protein expression levels in biopsies from 285 patients with RMBC, and the correlation between Tau expression and sensitivity to taxane was evaluated. One hundred twety-one (42.46 %, 121/285) patients were Tau positive in their tumor. One hundred ninety-four (68.07 %, 194/285) patients were effective clinical remission, which evaluated with response evaluation criteria in solid tumors (RECIST) criteria. In this group, 141 (85.98 %, 141/194) patients were Tau negative. We further analyzed the correlation between Tau expression and clinicopathological characteristics. Tau expression was positively correlated to estrogen receptor (ER) status. Multivariate logistic regression analysis showed that Tau expression significantly differentiated patients with effective response to treatment (95 % confidence interval (CI): 4.230–13.88, P < 0.01). Tau expression was identified as an independent factor to predict the sensitivity of tumors to taxane-containing palliative chemotherapy in RMBC, suggesting that Tau expression in RMBC may serve as a clinical predictor for taxane-containing palliative chemotherapy.

Qiu J, Yang M, Chen W, Gao X, Liu S, Shi S, et al. Prevalence and correlates of major depressive disorder in breast cancer survivors in Shanghai, China. Psycho-Oncology. 2012;21:1331–7.CrossRefPubMed

Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.CrossRefPubMed

Christiansen P, Al-Suliman N, Bjerre K, Møller S. Recurrence pattern and prognosis in low-risk breast cancer patients—data from the DBCG 89-A programme. Acta Oncol. 2008;47:691–703.CrossRefPubMed

Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück H-J, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26:1980–6.CrossRefPubMed

Cuppone F, Bria E, Carlini P, Milella M, Felici A, Sperduti I, et al. Taxanes as primary chemotherapy for early breast cancer. Cancer. 2008;113:238–46.CrossRefPubMed

Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, et al. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Ann Oncol. 2007;18:874–80.CrossRefPubMed

McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta (BBA) Rev Cancer. 2008;1785:96–132.CrossRef

Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, et al. Microtubule-associated protein Tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005;102:8315–20.CrossRefPubMedPubMedCentral

Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule associated protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle. 2005;4:1149–52.CrossRefPubMed

10.

Qin Y-Y, Li H, Guo X-J, Ye X-F, Wei X, Zhou Y-H, et al. Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30,698 patients. PLoS ONE. 2011;6:e26946.CrossRefPubMedPubMedCentral

11.

Drechsel DN, Hyman AA, Cobb MH, Kirschner MW. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein Tau. Mol Biol Cell. 1992;3:1141–54.CrossRefPubMedPubMedCentral

12.

Smith CJ, Anderton BH, Davis DR, Gallo JM. Tau isoform expression and phosphorylation state during differentiation of cultured neuronal cells. FEBS Lett. 1995;375:243–8.CrossRefPubMed

13.

Kar S, Fan J, Smith MJ, Goedert M, Amos LA. Repeat motifs of tau bind to the insides of microtubules in the absence of taxol. EMBO J. 2003;22:70–7.CrossRefPubMedPubMedCentral

14.

Li Z-H, Xiong Q-Y, Tu J-H, Gong Y, Qiu W, Zhang H-Q, et al. Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy. Med Oncol. 2013;30:1–7.

15.

Wang K, Deng Q-T, Liao N, Zhang G-C, Liu Y-H, Xu F-P, et al. Tau expression correlated with breast cancer sensitivity to taxanes-based neoadjuvant chemotherapy. Tumor Biol. 2013;34:33–8.CrossRef

16.

Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18:1133–44.CrossRefPubMed

17.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMed

18.

Ellis MJ. Mutational analysis of breast cancer: guiding personalized treatments. Breast (Edinburgh, Scotland). 2013;22:S19–21.CrossRef

19.

Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–83.CrossRefPubMed

20.

Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23:3686–96.CrossRefPubMed

21.

Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007;357:1496–506.CrossRefPubMed

22.

Murray S, Briasoulis E, Linardou H, Bafaloukos D, Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat Rev. 2012;38:890–903.CrossRefPubMed

23.

Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007;12:271–80.CrossRefPubMed

24.

Noguchi S. Predictive factors for response to docetaxel in human breast cancers. Cancer Sci. 2006;97:813–20.CrossRefPubMed

25.

Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, et al. Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein Tau, is highly predictive of tumor response. Breast. 2007;16:86–93.CrossRefPubMed

26.

Pentheroudakis G, Kalogeras K, Wirtz R, Grimani I, Zografos G, Gogas H, et al. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat. 2009;116:131–43.CrossRefPubMed

27.

Pusztai L, Jeong J-H, Gong Y, Ross JS, Kim C, Paik S, et al. Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol. 2009;27:4287–92.CrossRefPubMedPubMedCentral

28.

Dumontet C, Krajewska M, Treilleux I, Mackey JR, Martin M, Rupin M, et al. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy. Clin Cancer Res. 2010;16:3988–97.CrossRefPubMed

29.

Spicakova T, O’Brien MM, Duran GE, Sweet-Cordero A, Sikic BI. Expression and silencing of microtubule-associated protein Tau in breast cancer cells. Mol Cancer Ther. 2010;9:2970–81.CrossRefPubMedPubMedCentral

30.

Andre F, Hatzis C, Anderson K, Sotiriou C, Mazouni C, Mejia J, et al. Microtubule-associated protein-Tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res. 2007;13:2061–7.CrossRefPubMed

31.

Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, et al. Stathmin expression and its relationship to microtubule-associated protein Tau and outcome in breast cancer. Cancer. 2012;118:4660–9.CrossRefPubMedPubMedCentral

32.

Matsuno A, Takekoshi S, Sanno N, Utsunomiya H, Ohsugi Y, Saito N, et al. Modulation of protein kinases and microtubule-associated proteins and changes in ultrastructure in female rat pituitary cells: effects of estrogen and bromocriptine. J Histochem Cytochem. 1997;45:805–13.CrossRefPubMed

33.

Ferreira A, Caceres A. Estrogen-enhanced neurite growth: evidence for a selective induction of tau and stable microtubules. J Neurosci. 1991;11:392–400.PubMed

34.

West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci. 2001;98:11462–7.CrossRefPubMedPubMedCentral

35.

Ikeda H, Taira N, Hara F, Fujita T, Yamamoto H, Soh J, et al. The estrogen receptor influences microtubule-associated protein Tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells. Breast Cancer Res. 2010;12:R43.CrossRefPubMedPubMedCentral

36.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, et al. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat. 2008;116:131–43.CrossRefPubMed

Title: Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy
Authors: Jie Zhou
Shikun Qian
Hongsheng Li
Weixing He
Xiaojun Tan
Qiong Zhang
Guodong Han
Guiquan Chen
Rongcheng Luo
Publication date: 01-05-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3037-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

The 7th AJCC/UICC TNM staging system may be not suitable in predicting prognosis of synchronous multiple gastric carcinoma patients with D2 gastrectomy

Protein interactions of cortactin in relation to invadopodia formation in metastatic renal clear cell carcinoma

p21-Activated kinase 5 affects cisplatin-induced apoptosis and proliferation in hepatocellular carcinoma cells

Inhibition of progression of PanIN through antagonizing EGFR

Genetic variations in monocarboxylate transporter genes as predictors of clinical outcomes in non-small cell lung cancer

Note of clarification of data in the paper titled X-ray repair cross-complementing group 1 codon 399 polymorphism and lung cancer risk: an updated meta-analysis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer